dc.contributor.author
Herwig, Susanne
dc.contributor.author
Adler, Julia M.
dc.contributor.author
Vladimirova, Daria
dc.contributor.author
Trimpert, Jakob
dc.contributor.author
Sehouli, Jalid
dc.contributor.author
Cichon, Günter
dc.date.accessioned
2024-05-15T13:45:09Z
dc.date.available
2024-05-15T13:45:09Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/43569
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-43285
dc.description.abstract
During the COVID-19 pandemic, the early emergence of viral variants repeatedly undermined the effects of vaccination. Our aim here is to explore strategies for improving spike vaccine gene antigenicity by merging mutations from different variants of concern (VOCs) in a single vaccine gene. To this end, newly developed recombinant vaccine genes were designed, cloned into adenoviral vectors, and applied to C57BL/6 mice; then, serum-neutralizing antibodies against the wildtype SARS-CoV-2 strains were determined in neutralization assays. The merger of mutations from different variants of concern (alpha, beta, gamma, and delta) in a single recombinant spike-based vaccine gene provided a substantial improvement in neutralizing immunity to all variants of concern, including the omicron strains. To date, only unmodified spike genes of the original SARS-CoV-2 Wuhan strain (B.1) or dominant variants (BA.1, BA.5, and XBB.1.5) have been used as vaccine genes. The employment of unmodified vaccine genes is afflicted by limited cross-protection among variant strains. In contrast, recombinant vaccine genes that combine mutations from different strains in a single gene hold the potential to broaden and improve immune protection and might help to reduce the need for frequent vaccine adaptations in the future.
en
dc.format.extent
8 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
SARS-CoV-2 vaccine
en
dc.subject
neutralizing antibodies
en
dc.subject
vaccine genes
en
dc.subject
cross protection
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.title
Improving the Antigenicity of SARS-CoV-2 Vaccine Genes by Merging Mutations from Different Variants of Concern
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
248
dcterms.bibliographicCitation.doi
10.3390/vaccines12030248
dcterms.bibliographicCitation.journaltitle
Vaccines
dcterms.bibliographicCitation.number
3
dcterms.bibliographicCitation.originalpublishername
MDPI
dcterms.bibliographicCitation.volume
12
dcterms.bibliographicCitation.url
https://doi.org/10.3390/vaccines12030248
refubium.affiliation
Veterinärmedizin
refubium.affiliation.other
Institut für Virologie
![This authority value has been confirmed as accurate by an interactive user](/cache_202e45ad85b55efaeb29160f63cd3f3b/themes/FuCD/images/authority_control/invisible.gif)
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
2076-393X